Litecoin Could See ETFs Before Solana & XRP – As Sui and Remittix Tipped For Huge Gains In 2025
Cassava Sciences’ stock craters after Alzheimer’s disease trial fails to meet its goals
The biotech says it will discontinue a second trial but will still offer full analyses of the data.